Navigation Links
Alzheimer's Association Grant Furthers Successful Research at UMass Lowell
Date:10/24/2008

'SmartPill' Uses Vitamin Formulation to Improve Brain Health, Memory

LOWELL, Mass., Oct. 24 /PRNewswire-USNewswire/ -- Researchers at UMass Lowell have demonstrated success in improving the memory and brain function of patients with Alzheimer's disease, findings that will be published in the December/January issue of the American Journal of Alzheimer's Disease.

Called the "SmartPill," the vitamin-based formulation has been shown to improve memory and recall speed in normal adults and Alzheimer's patients, without side effects. On Monday, Oct. 20, the Alzheimer's Association presented a grant, awarded competitively at the national level, to support additional clinical trials to test whether the formulation can delay the onset of the disease.

James Wessler, president and CEO of the Massachusetts/New Hampshire Chapter of the Alzheimer's Association, presented a check for $240,000 for three years to UMass Lowell Prof. Thomas Shea, the lead researcher on the "SmartPill." A licensing agreement to bring the pill to the market under the name MemoryXL to be sold without a prescription is in negotiations.

"This formulation is the first, non-prescription, low-cost intervention for Alzheimer's disease," says Shea, a professor in UMass Lowell's Biological Sciences Department. "One can start this at the first indication of memory problems, or even before for general brain health, instead of waiting for the severe deterioration of advancing Alzheimer's."

Shea, representatives of the Alzheimer's Association's Massachusetts/New Hampshire Chapter and UMass Lowell, including Chancellor Marty Meehan, were among those who attended the presentation, which was held on the UMass Lowell campus.

Wessler said at the event, "Prof. Shea's work couldn't be more important. If we can push back by five years the onset of Alzheimer's, then 50 percent of today's Americans - who would otherwise get the disease - will never experience Alzheimer's."

"Prof. Shea's important research combines scientific rigor with an eye on the end result. He has increased our understanding of Alzheimer's disease, but he's doing even more to improve the brain functioning and quality of life for patients," said Meehan. "We're moving quickly to share the good results. We want to see innovation in the lab translated into real products that make a difference in people's lives."

For more on living with Alzheimer's disease, call the Alzheimer's Association help line at 800-272-3900 or check out http://www.alz.org/MA.


'/>"/>
SOURCE University of Massachusetts Lowell
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. American Heart Association Comment Saving Lives in Type 2 Diabetics: Could It Be as Easy as Lowering Blood Pressure?
2. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
3. Terumo Heart to Announce Results of European Clinical Trial of DuraHeart(TM) LVAS at European Association of Cardiothoracic Surgeons Meeting in September
4. Hypertension: Journal of the American Heart Association Rapid Access Reports: Hispanics Hypertension Better Controlled With Equal Access to Care
5. American Fertility Association Calls for Expanded Research to Advance New Technology to Screen Embryos for Genetic Abnormalities
6. Actress and Mother Jennifer Garner Joins American Lung Association to Encourage Americans to Get an Influenza Vaccination
7. Genaera Corporation Presents Preclinical Trodusquemine (MSI-1436) Data at the North American Association for the Study of Obesity Annual Meeting
8. Genaera Corporation Presents Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
9. Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
10. Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting
11. MedicAlert Foundation Joins The Alzheimers Association to Offer MedicAlert(R) + Alzheimers Association Safe Return(R) - Live 24-Hour Emergency Response for Wandering and Medical Emergencies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... CITY, Calif., Feb. 23, 2017 Nevro Corp. (NYSE: ... evidence-based solutions for the treatment of chronic pain, today reported ... December 31, 2016. 2016 Accomplishment & Highlights: ... full year 2016, an increase of 228% as reported, over ... for 2016, an increase of 612% over the prior year ...
(Date:2/23/2017)... Research and Markets has announced the addition of the ... to their offering. ... The latest research Fibromyalgia Drugs Price Analysis and Strategies - ... market. The research answers the following questions: ... their clinical attributes? How are they positioned in the Global Fibromyalgia ...
(Date:2/23/2017)... , February 23, 2017 ... Market by Product (X-ray Imaging Digital, Analog), MRI (Closed, ... (OB/GYN, MSK, Cardiology, Oncology), End User (Hospitals, Imaging Centers) ... report studies the global market over the forecast period ... reach ~USD 36.43 Billion by 2021, at a CAGR ...
Breaking Medicine Technology:
(Date:2/23/2017)... CA (PRWEB) , ... February 23, 2017 , ... Hamlin ... to announce that they are sponsoring a raffle. Throughout the month of February, patients ... will receive a gift card for a dinner for two at the Cheesecake Factory. ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... for the National Institute for Health and Care Excellence (NICE) framework. ... the National Health Service (NHS) to search, order and purchase medical and healthcare-related ...
(Date:2/23/2017)... ... 23, 2017 , ... Dr. David Mahon leads Siena Dental, a comprehensive dental ... named a 2017 Top Patient Rated Henderson Dentist by Find Local Doctors ... local physicians and dentists who have earned high ratings and superior patient reviews from ...
(Date:2/23/2017)... ... , ... ERT, a global data and technology company that ... leading clinical development service provider, has selected ERT’s Trial Oversight suite as its ... to an array of circumstances including the use of multiple data capture modalities ...
(Date:2/23/2017)... ... February 23, 2017 , ... Healthcare Research & Analytics® (HRA®) ... fight against cancer, has produced a seminal study that asked cancer survivors and ... findings in a webinar, Defining Compassionate Care Through the Voices of Patients and ...
Breaking Medicine News(10 mins):